Berberine

Berberine

SCHEMBL3686644

COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2.N

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 10/20 0.98
BCHE P06276 9/20 0.98
EP300 Q09472 6/20 0.98
CYP3A4 P08684 4/20 0.98
MAPT P10636 4/20 0.98
RAD52 P43351 4/20 0.98
LMNA P02545 3/20 0.98
CYP2D6 P10635 3/20 0.98
ALDH1A1 P00352 2/20 0.98
CHRM1 P11229 2/20 0.98
DRD2 P14416 2/20 0.98
TSHR P16473 2/20 0.98
ADRA2B P18089 2/20 0.98
ADRA2C P18825 2/20 0.98
RXRA P19793 2/20 0.98
DRD1 P21728 2/20 0.98
HTR2B P41595 2/20 0.98
HTT P42858 2/20 0.98
KCNH2 Q12809 2/20 0.98
SMN1; SMN2 Q16637 2/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Berberine SCHEMBL30153843 0.99 ACHE (1.00) ACHEBCHEEP300CYP3A4MAPT
Berberine SCHEMBL25632 0.99 ACHE (1.00) ACHEBCHEEP300CYP3A4MAPT
Berberine SCHEMBL15669190 0.99 ACHE (1.00) ACHEBCHEEP300CYP3A4MAPT
Berberine SCHEMBL29354144 0.99 ACHE (1.00) ACHEBCHEEP300CYP3A4MAPT
Berberine SCHEMBL1376273 0.98 ACHE (0.98) ACHEBCHEEP300CYP3A4MAPT
Berberine SCHEMBL4894622 0.98 BCHE (0.98) ACHEBCHEEP300CYP3A4MAPT
Berberine SCHEMBL21462194 0.98 ACHE (0.98) ACHEBCHEEP300CYP3A4MAPT
Berberine SCHEMBL10709599 0.98 ACHE (0.98) ACHEBCHEEP300CYP3A4MAPT
Berberine SCHEMBL153906 0.98 ACHE (1.00) ACHEBCHEEP300CYP3A4MAPT
Berberine SCHEMBL2538316 0.98 ACHE (0.98) ACHEBCHEEP300CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230404107-A1 BERBERINE ALKALOIDS IN THE PREVENTION AND/OR TREATMENT OF INTESTINAL DISEASE IRP Health Pty Ltd (AU) 2023-12-21 US disclosed
WO-2023115158-A1 COATING COMPOSITIONS Silfresh Pty Ltd (AU) 2023-06-29 WO disclosed
US-20210329946-A1 BERBERINE ALKALOID FORMULATIONS IN THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASE IRP Health Pty Ltd (AU) 2021-10-28 US disclosed
US-20210220335-A1 NITROIMIDAZOLE FORMULATIONS IRP Health Pty Ltd (AU) 2021-07-22 US disclosed
EP-3810137-A1 NITROIMIDAZOLE FORMULATIONS IRP Health Pty Ltd (AU) 2021-04-28 EP disclosed
WO-2021072473-A1 ANTIMICROBIALS AS FEED PRESERVATIVES IRP Health Pty Ltd (AU) 2021-04-22 WO disclosed
CN-112543635-A Nitroimidazole formulations IRP健康股份有限公司 2021-03-23 CN disclosed
EP-3600305-A1 BERBERINE ALKALOID FORMULATIONS IN THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASE IRP Health Pty Ltd (AU) 2020-02-05 EP disclosed
EP-3600304-A1 BERBERINE ALKALOIDS IN THE PREVENTION AND/OR TREATMENT OF INTESTINAL DISEASE IRP Health Pty Ltd (AU) 2020-02-05 EP disclosed
CN-110709080-A Use of berberine alkaloid preparation in preventing and/or treating infectious diseases IRP健康股份有限公司 2020-01-17 CN disclosed
CN-110650739-A Use of berberine alkaloid in preventing and/or treating intestinal diseases IRP健康股份有限公司 2020-01-03 CN disclosed
WO-2019227149-A1 NITROIMIDAZOLE FORMULATIONS IRP Health Pty Ltd (AU) 2019-12-05 WO disclosed
WO-2019196955-A1 HYDROPHILIC BERBERINE DERIVATIVE WITH R10 AND R11 CONNECTED AND APPLICATION THEREOF IN PREPARATION OF DRUGS 中国医学科学院药物研究所 2019-10-17 WO disclosed
WO-2019196957-A1 HYDROPHILIC BERBERINE-TYPE DERIVATIVE AND APPLICATION THEREOF IN PREPARING DRUG 中国医学科学院药物研究所 2019-10-17 WO disclosed
WO-2018176093-A1 BERBINE ALKALOID FORMULATIONS IN THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASE IRICCORGPHARM PTY LTD (AU) 2018-10-04 WO disclosed
WO-2018176079-A1 BERBERINE ALKALOIDS IN THE PREVENTION AND/OR TREATMENT OF INTESTINAL DISEASE IRICCORGPHARM PTY LTD (AU) 2018-10-04 WO disclosed
US-20100292178-A1 Method of treating non-insulin dependent diabetes mellitus and related complications YOUNG JEFFREY 2010-11-18 US disclosed
US-20050019435-A1 Method of treating non-insulin dependent diabetes mellitus and related complications YOUNG JEFFREY (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210220335-A1 NITROIMIDAZOLE FORMULATIONS PHB1, COX5B, CYP3A5 ACHE 1722/4885BCHE 287/4885EP300 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.